This commentary analyzes the Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results (LEADER) trial, which has reported the cardiovascular …

Cardiovascular disease (CVD) is the leading cause of death and one of the common
diabetes-related complications in patients with type 2 diabetes1. After the US Food and Drug …

Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk
for a broad range of adverse cardiovascular outcomes including coronary heart disease …

Diabetes mellitus (DM) is a chronic metabolic disorder, with type 2 diabetes (T2DM)
significantly impacting the cardiovascular (CV) system. Our comprehensive study on the …

OBJECTIVE The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) trial (ClinicalTrials. gov reg. no. NCT01179048) demonstrated a …

Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue,
when added to standard care in patients with type 2 diabetes, remains unknown. Methods In …

Metformin is the first-line therapy for the management of type 2 diabetes. After 3 months of
metformin, add-on therapy can be considered if an individual's glycemic control has not …

Type 2 diabetes mellitus (T2DM) substantially increases risk of cardiovascular disease
(CVD). However, whether glucose-lowering agents improve CV health is controversial …

Background: Liraglutide is a glucagon-like 1 (GLP-1) agonist approved for treatment of type
2 diabetes and obesity. Objective: To review the cardiovascular effects of liraglutide …

ABSTRACT Review of: Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and
Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311–322. Mann J …